BIOHARVEST SCIENCES INC
BHSTNASDAQTrading Snapshot
- Day Range
- $1.65 – $1.76
- 52-Week Range
- $0.14 – $0.38
- Volume (shares)
- 20,426
- Avg Volume (shares)
- —
- Shares Outstanding
- 22.7M
- Next Earnings
- 2026-11-12
Fundamentals Snapshot
- Annual Revenue
- $35M
- Last Q Revenue
- $9M
- P/E Ratio
- —
- P/S Ratio
- 2.5x
- EPS (TTM)
- $-1.19
- Dividend Yield
- —
- Dilution (1yr)
- +6.3%
BIOHARVEST SCIENCES INC
BHST
StockOtter · stockotter.spaceAbout BIOHARVEST SCIENCES INC
BioHarvest Sciences Inc. functions as a biotechnology firm with operations segmented into Nutraceuticals and Pharmaceuticals. A key innovation is its proprietary botanical synthesis platform technology, which allows for the cultivation of active ingredients found within plant enzymes or cells. The company harnesses this advanced technology to craft evidence-based and clinically validated therapeutic products for both its nutraceutical and pharmaceutical offerings. Beyond its own development, it also provides contract development and manufacturing services. Its product portfolio includes various wellness items, notably VINIA, a dietary supplement derived from red grape cells, which delivers the full spectrum of polyphenols naturally present in red grapes. The company conducts business in Israel and the United States, with its corporate base in Vancouver, Canada.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
BioHarvest Sciences to Report Third Quarter 2026 Financial Results on November 12, 2026
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 29, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis tec
BioHarvest takes second plant-cell asset to commercial readiness
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Tuesday that Olive Cell, an olive-derived plant-cell ingredient, is ready for commercial licensing, the second product from its Botanical Synthesis technology to re
BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity
Botanical Synthesis™-developed asset has now completed development, commercial-scale manufacturing and the applicable self-affirmed GRAS process and is ready for production at BioHarvest's GMP facility Milestone demonstr
BioHarvest says its platform can produce target sweetener in Tate & Lyle program
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Thursday its Botanical Synthesis platform can produce the next-generation sweetener targeted in its joint development program with Tate & Lyle. Tate & Lyle, a supp
Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme
Progress demonstrates that BioHarvest's Botanical Synthesis(TM) platform is capable of producing the targeted next-generation sweetening solution Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October
BioHarvest Sciences launches buyback of up to 5% of shares
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said Tuesday its board has authorized a share repurchase program covering up to 5% of its outstanding common shares. The company, which develops and manufactures proprieta